Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.69% is 237% above its 5-year average of -72.82%, near the high end of its 5-year range (-36792.31%–100.00%).
0.52% above its 12-month average of 99.17%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 99.54%.
GROSS MARGIN
99.69%
GROSS MARGIN AVG TTM
99.17%
GROSS MARGIN AVG 3Y
99.95%
GROSS MARGIN AVG 5Y
-72.82%
GROSS MARGIN AVG 10Y
-376.27%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.52%
CURRENT VS 3Y AVG
-0.26%
CURRENT VS 5Y AVG
+236.89%
CURRENT VS 10Y AVG
+126.49%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+138.72%
vs the sector median at left
Cue Biopharma, Inc.
Market Cap
$173.89M
Gross Margin
99.69%
TTM Avg
99.17%
3Y Avg
99.95%
5Y Avg
-72.82%
Market Cap
$172.18M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$177.78M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$179.09M
Gross Margin
62.24%
TTM Avg
61.05%
3Y Avg
61.66%
5Y Avg
60.51%
Market Cap
$168.56M
Gross Margin
67.59%
TTM Avg
75.78%
3Y Avg
75.92%
5Y Avg
75.58%
Market Cap
$180.85M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | $173.89M | 99.69% | 99.17% | 99.95% | -72.82% |
| MediWound Ltd. (MDWD)vs › | $172.77M | 15.46% | 16.11% | 25.27% | 28.77% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.18M | 100.00% | 100.00% | 100.00% | 100.00% |
| Nkarta, Inc. (NKTX)vs › | $172.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| Compass Therapeutics, Inc. (CMPX)vs › | $177.78M | 0.00% | 50.00% | 25.00% | 16.67% |
| OptimizeRx Corp. (OPRX)vs › | $169.41M | 63.30% | 63.88% | 62.53% | 60.65% |
| Journey Medical Corporation (DERM)vs › | $179.09M | 62.24% | 61.05% | 61.66% | 60.51% |
| Organogenesis Holdings Inc. (ORGO)vs › | $168.56M | 67.59% | 75.78% | 75.92% | 75.58% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.85M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coherus Oncology, Inc. (CHRS)vs › | $165.32M | 63.55% | 56.95% | 54.72% | 65.55% |
Gross Margin
99.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 99.54% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 96.32% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | -640.64% |
| 2023-09-30 | -327.33% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | -5230.46% |
| 2022-09-30 | -11033.82% |
| 2022-06-30 | -36792.31% |
| 2022-03-31 | -908.20% |
| 2021-12-31 | -39.33% |
| 2021-09-30 | -371.32% |
| 2021-06-30 | -219.90% |
| 2021-03-31 | -532.07% |
| 2020-12-31 | -1583.84% |
| 2020-09-30 | -967.76% |
| 2020-06-30 | -655.26% |
| 2020-03-31 | -1000.67% |
| 2019-12-31 | -563.71% |
| 2019-09-30 | -438.82% |
| 2019-06-30 | -550.90% |
| 2019-03-31 | -2157.57% |
| 2018-12-31 | -1963.81% |
| 2018-09-30 | -2196.88% |
| 2018-06-30 | -3047.67% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
